ARTICLE | Clinical News
Priftin rifapentine: Phase III data
July 18, 2011 7:00 AM UTC
An open-label, South African Phase III trial in 1,148 HIV-infected adults with a positive tuberculin skin test who were not taking antiretroviral therapy showed that weekly 900 mg Priftin plus 900 mg ...